Hidden harm? Assessing magnitude and costs of intravenous therapy administration errors via smart pump reports

ABSTRACT

5PSQ-112 Table 1Conclusion and relevanceThe study identified an incidence rate above those in many published studies;this may be because we ‘cast the net wider’ and because in the areas studied there was limited clinician experience of administration of some of the medications. Competency is difficult to maintain with limited exposure to a task. The presence of insulin, potassium preparations, and cytotoxics in our results is in line with other studies. The cost savings indicate the potential value of smart intravenous technology being deployed in every part of the hospitalReferences and/or acknowledgements1. Manrique-Rodríguez, et al. Implementing smart pump technology in a pediatric intensive care unit a cost-effective approach. Int J Med Inform 2014;83(2)99–105.2. Khan, et al. Survival and estimation of direct medical costs of hospitalized COVID-19 patients in the Kingdom of Saudi Arabia. Int J Environ Res Public Health 2020;17(20)7458.Conflict of interestCorporate sponsored research or other substantive relationships advisory board for Becton Dickinson.